ABBOTT LABORATORIES · News & developments
Abbott’s $1.35 billion buyback update adds a capital-allocation tailwind
Source: Yahoo FinanceBullish
A Yahoo Finance headline reported that Abbott had provided a $1.35 billion buyback update and described the stock as potentially undervalued. The headline does not specify the authorization terms, execution schedule or shares repurchased.
Why this matters
Repurchases can increase per-share cash flow and EPS when funded sustainably and made below intrinsic value. The effect on valuation remains dependent on actual execution and the cash used relative to Abbott’s existing debt and investment needs.